Cited by 5,051Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and ManagementAcute Ischemic Stroke Management

The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

Ruff, Christian T, Giugliano, Robert P, Braunwald, Eugene, Hoffman, Elaine B, Deenadayalu, Naveen, Ezekowitz, Michael D, Camm, A John, Weitz, Jeffrey I, Lewis, Basil S, Parkhomenko, Alexander, Yamashita, Takeshi, Antman, Elliott M·2014·The Lancet

DOI 10.1016/s0140-6736(13)62343-0

Open this paper in CoChat — free account

Abstract

Background Four new oral anticoagulants compare favourably with warfarin for stroke prevention in patients with atrial fibrillation; however, the balance between efficacy and safety in subgroups needs better definition. We aimed to assess the relative benefit of new oral anticoagulants in key subgroups, and the effects on important secondary outcomes.Methods We searched Medline from Jan 1, 2009, to Nov 19, 2013, limiting searches to phase 3, randomised trials of patients with atrial fibrillation who were randomised to receive new oral anticoagulants or warfarin, and trials in which both efficacy and safety outcomes were reported. We did a prespecified meta-analysis of all 71,683 participants included in the RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48 trials. The main outcomes were stroke and systemic embolic events, ischaemic stroke, haemorrhagic stroke, all-cause mortality, myocardial infarction, major bleeding, intracranial haemorrhage, and gastrointestinal bleeding. We calculated relative risks (RRs) and 95% CIs for each outcome. We did subgroup analyses to assess whether differences in patient and trial characteristics affected outcomes. We used a random-effects model to compare pooled outcomes and tested for heterogeneity.Findings 42,411 participants received a new oral anticoagulant and 29,272 participants received warfarin. New oral anticoagulants significantly reduced stroke or systemic embolic events by 19% compared with warfarin (RR 0·81, 95% CI 0·73-0·91; p<0·0001), mainly driven by a reduction in haemorrhagic stroke (0·49, 0·38-0·64; p<0·0001). New oral anticoagulants also significantly reduced all-cause mortality (0·90, 0·85-0·95; p=0·0003) and intracranial haemorrhage (0·48, 0·39-0·59; p<0·0001), but increased gastrointestinal bleeding (1·25, 1·01-1·55; p=0·04). We noted no heterogeneity for stroke or systemic embolic events in important subgroups, but there was a greater relative reduction in major bleeding with new oral anticoagulants when the centre-based time in therapeutic range was less than 66% than when it was 66% or more (0·69, 0·59-0·81 vs 0·93, 0·76-1·13; p for interaction 0·022). Low-dose new oral anticoagulant regimens showed similar overall reductions in stroke or systemic embolic events to warfarin (1·03, 0·84-1·27; p=0·74), and a more favourable bleeding profile (0·65, 0·43-1·00; p=0·05), but significantly more ischaemic strokes (1·28, 1·02-1·60; p=0·045).Interpretation This meta-analysis is the first to include data for all four new oral anticoagulants studied in the pivotal phase 3 clinical trials for stroke prevention or systemic embolic events in patients with atrial fibrillation. New oral anticoagulants had a favourable risk-benefit profile, with significant reductions in stroke, intracranial haemorrhage, and mortality, and with similar major bleeding as for warfarin, but increased gastrointestinal bleeding. The relative efficacy and safety of new oral anticoagulants was consistent across a wide range of patients. Our findings offer clinicians a more comprehensive picture of the new oral anticoagulants as a therapeutic option to reduce the risk of stroke in this patient population.Funding None.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(13)62343-0

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Kirchhof, P. F., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Gelder, I. C. V., Al‐Attar, N., Hindricks, G., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq278 · Cited by 5,924
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation
Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J. G. M., & Lip, G. Y. H. (2010) · CHEST Journal · doi:10.1378/chest.10-0134 · Cited by 4,517

Show all 45 references

Sorted by citations

Items 701–800 of 1,004

Timing of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation: study protocol for a registry-based randomised controlled trial
Åsberg, S., Hijazi, Z., Norrving, B., Terént, A., Öhagen, P., & Oldgren, J. (2017) · Trials · doi:10.1186/s13063-017-2313-9 · Cited by 43
“NOAC may offer several potential advantages in the acute setting after ischemic stroke in AF patients; all NOAC have a much faster and more predictable onset of action and, most importantly, a substantial lower risk of ICH compared to warfarin [8, 9].”
Background
Ex vivo reversal of the anticoagulant effects of edoxaban
Halim, A., Samama, M. M., & Mendell, J. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.07.036 · Cited by 43
Burden of major gastrointestinal bleeding among oral anticoagulant-treated non-valvular atrial fibrillation patients
Deitelzweig, S. B., Keshishian, A. V., Kang, A. L., Dhamane, A. D., Luo, X., Balachander, N., Rosenblatt, L. C., Mardekian, J., Jiang, J. Z., Yüce, H., et al. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284821997352 · Cited by 43
JCS / JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias
Ono, K., Iwasaki, Y., Akao, M., Ikeda, T., Ishii, K., Inden, Y., Kusano, K., Kobayashi, Y., Koretsune, Y., Sasano, T., et al. (2022) · Journal of Arrhythmia · doi:10.1002/joa3.12714 · Cited by 41
Rationale and design of a randomized study comparing the Watchman FLX device to DOACs in patients with atrial fibrillation
Kar, S., Doshi, S. K., Alkhouli, M. A., Camm, A. J., Coylewright, M. J., Gibson, C. M., Granger, C. B., Gurol, M. E., Huber, K., MANSOUR, M. C., et al. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.05.022 · Cited by 43
Long-term warfarin therapy and biomarkers for osteoporosis and atherosclerosis
Namba, S., Yamaoka‐Tojo, M., Hashikata, T., Ikeda, Y., Kitasato, L., Hashimoto, T., Shimohama, T., Tojo, T., Takahira, N., Masuda, T., et al. (2015) · BBA Clinical · doi:10.1016/j.bbacli.2015.08.002 · Cited by 43
Initial management and timing of endoscopy in nonvariceal upper GI bleeding
Kumar, N. L., Travis, A. C., & Saltzman, J. R. (2016) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2016.02.031 · Cited by 41
Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis
Petzold, T., Thienel, M., Konrad, I., Schubert, I., Regenauer, R., Hoppe, B. F., Lorenz, M. C., Eckart, A., Chandraratne, S., Lennerz, C., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad6712 · Cited by 44
Periendoscopic management of direct oral anticoagulants: a prospective cohort study
Radaelli, F., Fuccio, L., Paggi, S., Hassan, C., Repici, A., Rondonotti, E., Semeraro, R., Leo, M. D., Anderloni, A. A., Amato, A., et al. (2018) · Gut · doi:10.1136/gutjnl-2018-316385 · Cited by 43
Two-Year Outcomes of Anticoagulation for Acute Ischemic Stroke With Nonvalvular Atrial Fibrillation ― SAMURAI-NVAF Study ―
Yoshimura, S., Koga, M., Sato, S., Todo, K., Yamagami, H., Kumamoto, M., Itabashi, R., Terasaki, T., Kimura, K., Yagita, Y., et al. (2018) · Circulation Journal · doi:10.1253/circj.cj-18-0067 · Cited by 43
Non–Vitamin K Antagonist Oral Anticoagulants for Mechanical Heart Valves
Aimo, A., Giugliano, R. P., & Caterina, R. D. (2018) · Circulation · doi:10.1161/circulationaha.118.035612 · Cited by 43
CHA2DS2‐VASc score predicts atrial fibrillation recurrence after cardioversion: Systematic review and individual patient pooled meta‐analysis
Vitali, F., Serenelli, M., Airaksinen, J. K. E., Pavasini, R., Tomaszuk−Kazberuk, A., Młodawska, E., Jaakkola, S., Balla, C., Falsetti, L., Tarquinio, N., et al. (2018) · Clinical Cardiology · doi:10.1002/clc.23147 · Cited by 45
Clinical and Economic Implications of AF Related Stroke.
Ali, A., & Abdelhafiz, A. H. (2016) · PubMed Central · doi:10.4022/jafib.1279 · Cited by 43
Anticoagulant-associated intracerebral hemorrhage
Morotti, A., & Goldstein, J. N. (2020) · Brain Hemorrhages · doi:10.1016/j.hest.2020.01.001 · Cited by 45
GARFIELD-AF: A Worldwide Prospective Registry of Patients With Atrial Fibrillation at Risk of Stroke
Bassand, J., Apenteng, P. N., Atar, D., Camm, A. J., Cools, F. J. S., Corbalan, R. L., Fitzmaurice, D. A., Fox, K. A. A., Goto, S., Haas, S. K., et al. (2020) · Future Cardiology · doi:10.2217/fca-2020-0014 · Cited by 48
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source
Shoamanesh, A., Hart, R. G., Connolly, S. J., Kasner, S. E., Smith, E. E., Martí‐Fábregas, J., Liu, Y., Uchiyama, S., Mikulík, R., Veltkamp, R. C., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.3836 · Cited by 43
Discontinuation of oral anticoagulation in atrial fibrillation and risk of ischaemic stroke
Rodríguez, L. A. G., Soriano, L. C., Hald, S. M., Hallas, J., Balabanova, Y., Brobert, G., Vora, P., Sharma, M., & Gaist, D. (2020) · Heart · doi:10.1136/heartjnl-2020-317887 · Cited by 43
The Interactions of Nintedanib and Oral Anticoagulants—Molecular Mechanisms and Clinical Implications
Grześk, G., Woźniak-Wiśniewska, A., Błażejewski, J., Górny, B., Wołowiec, Ł., Rogowicz, D., & Nowaczyk, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010282 · Cited by 43
Ethnic Diversity and Warfarin Pharmacogenomics
Asiimwe, I. G., & Pirmohamed, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.866058 · Cited by 44
Novel Antithrombotic Drugs on the Horizon
McFadyen, J. D., & Peter, K. (2017) · Circulation Research · doi:10.1161/circresaha.117.312012 · Cited by 43
Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week
Caterina, R. D., Agewall, S., Andreotti, F., Angiolillo, D. J., Bhatt, D. L., Byrne, R. A., Collet, J., Eikelboom, J. W., Fanaroff, A. C., Gibson, C. M., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac294 · Cited by 44
Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention
Camm, A. J., Fox, K. A. A., & Peterson, E. D. (2017) · EP Europace · doi:10.1093/europace/eux086 · Cited by 42
Neutrophil extracellular traps (NETs) infiltrate haematoma and surrounding brain tissue after intracerebral haemorrhage: A post‐mortem study
Puy, L., Corseaux, D., Perbet, R., Deramecourt, V., Cordonnier, C., & Bérézowski, V. (2021) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12733 · Cited by 46
Bleeding related to oral anticoagulants: Trends in US emergency department visits, 2016-2020
Geller, A. I., Shehab, N., Lovegrove, M. C., Weidle, N. J., & Budnitz, D. S. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.03.010 · Cited by 42
Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?
Cross, B., Turner, R. M., Zhang, E. J., & Pirmohamed, M. (2024) · The Pharmacogenomics Journal · doi:10.1038/s41397-024-00329-y · Cited by 45
Left Atrial Appendage Closure Compared With Oral Anticoagulants for Patients With Atrial Fibrillation: A Systematic Review and Network Meta‐Analysis
Oliva, A., Ioppolo, A. M., Chiarito, M., Cremonesi, A., Azzano, A., Miccichè, E., Mangiameli, A., Ariano, F., Ferrante, G., Reimers, B., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.034815 · Cited by 42
Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis
Philippart, R., Brunet-Bernard, A., Clémenty, N., Bourguignon, T., Mirza, A., Angoulvant, D., Babuty, D., Lip, G. Y. H., & Fauchier, L. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-01-0007 · Cited by 42
Outcome of intracerebral haemorrhage related to non-vitamin K antagonists oral anticoagulants versus vitamin K antagonists: a comprehensive systematic review and meta-analysis
Boulouis, G., Morotti, A., Pasi, M., Goldstein, J. N., Gurol, M. E., & Charidimou, A. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316631 · Cited by 42
Restarting oral anticoagulant therapy after major bleeding in atrial fibrillation: A systematic review and meta-analysis
Proietti, M., Romiti, G. F., Romanazzi, I., Farcomeni, A., Stærk, L., Nielsen, P. B., & Lip, G. Y. H. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.03.053 · Cited by 42
A simple and fast HPLC-MS/MS method for simultaneous determination of direct oral anticoagulants apixaban, dabigatran, rivaroxaban in human plasma
Lagoutte‐Renosi, J., Poupon, J. L., Girard, A., Montange, D., & Davani, S. (2018) · Journal of Chromatography B · doi:10.1016/j.jchromb.2018.09.026 · Cited by 42
Direct oral anticoagulants: a review of common medication errors
Barr, D., & Epps, Q. J. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1752-9 · Cited by 43
Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding
Arachchillage, D. J., Alavian, S., Griffin, J., Gurung, K., Szydlo, R., Karawitage, N., & Laffan, M. (2018) · British Journal of Haematology · doi:10.1111/bjh.15705 · Cited by 42
Effect of a Quality Improvement Intervention on Adherence to Therapies for Patients With Acute Ischemic Stroke and Transient Ischemic Attack
Machline-Carrion, M. J., Santucci, E. V., Damiani, L. P., Bahit, M. C., Málaga, G., Pontes‐Neto, O. M., Martins, S. C. O., Zétola, V. D. H. F., Normílio-Silva, K., de Freitas, G. R., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1012 · Cited by 45
A Review of the Incidence Diagnosis and Treatment of Spontaneous Hemorrhage in Patients Treated with Direct Oral Anticoagulants
Gunasekaran, K., Rajasurya, V., Devasahayam, J. V. M., Rahi, M. S., Chandran, A., Elango, K., & Talari, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092984 · Cited by 48
Different DOACs Control Inflammation in Cardiac Ischemia-Reperfusion Differently
Gadi, I., Fatima, S., Elwakiel, A., Nazir, S., Al‐Dabet, M. M., Rana, R., Bock, F. M., Manoharan, J., Gupta, D., Biemann, R., et al. (2020) · Circulation Research · doi:10.1161/circresaha.120.317219 · Cited by 41
Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy
Magnocavallo, M., Bellasi, A., Mariani, M., Fusaro, M., Ravera, M., Paoletti, E., Iorio, B. D. D., Bàrbera, V., Rocca, D. D., Palumbo, R., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm10010083 · Cited by 39
A Proposed Strategy for Anticoagulation Therapy in Noncompaction Cardiomyopathy
Chimenti, C., Lavalle, C., Magnocavallo, M., Alfarano, M., Mariani, M. V., Bernardini, F., Rocca, D. G. D., Galardo, G., Severino, P., Lullo, L. D., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13694 · Cited by 42
Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?
Chan, N., Sager, P. T., Lawrence, J., Ortel, T., Reilly, P. A., Berkowitz, S. D., Kubitza, D., Eikelboom, J. W., Florian, J. A., Stockbridge, N., et al. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.10.002 · Cited by 41
Atrial fibrillation in aging population
Chen, Q., Zhong, Y., & Cheng, J. (2018) · Aging Medicine · doi:10.1002/agm2.12015 · Cited by 41
How to Monitor Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Practice Tool Endorsed by Thrombosis Canada, the Canadian Stroke Consortium, the Canadian Cardiovascular Pharmacists Network, and the Canadian Cardiovascular Society
Gladstone, D. J., Geerts, W. H., Douketis, J. D., Ivers, N. M., Healey, J. S., & Leblanc, K. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0143 · Cited by 41
Effects of Regional Differences in Asia on Efficacy and Safety of Edoxaban Compared With Warfarin – Insights From the ENGAGE AF-TIMI 48 Trial –
Shimada, Y. J., Yamashita, T., Koretsune, Y., Kimura, T., Abe, K., Sasaki, S., Mercuri, M. F., Ruff, C. T., & Giugliano, R. P. (2015) · Circulation Journal · doi:10.1253/circj.cj-15-0574 · Cited by 41
Rationale and design of the RE-LATED AF—AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus—Effects of Dabigatran in patients with Atrial Fibrillation
Ferner, M., Wachtlin, D., Konrad, T., Deuster, O., Meinertz, T., von Bardeleben, S., Münzel, T. F., Seibert‐Grafe, M., BREITHARDT, G. E., & Rostock, T. (2015) · Clinical Research in Cardiology · doi:10.1007/s00392-015-0883-7 · Cited by 41
Automated Software System to Promote Anticoagulation and Reduce Stroke Risk
Holt, T., Dalton, A., Marshall, T. P., Fay, M., Qureshi, N., Kirkpatrick, S., Hislop, J., Lasserson, D. S., Kearley, K. E., Mollison, J., et al. (2017) · Stroke · doi:10.1161/strokeaha.116.015468 · Cited by 41
Postapproval Observational Studies of Non–Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation
Potpara, T., & Lip, G. Y. H. (2017) · JAMA · doi:10.1001/jama.2017.1152 · Cited by 41
Laboratory measurement of the direct oral anticoagulants: Indications and impact on management in clinical practice
Wright, C. M., Brown, R., & Cuker, A. C. (2017) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12654 · Cited by 41
Non–Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury
Douros, A., Azoulay, L., Yin, H., Suissa, S., & Renoux, C. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.01.009 · Cited by 40
Adherence to Oral Anticoagulants in Atrial Fibrillation: An Australian Survey
Obamiro, K. O., Chalmers, L., Lee, K., Bereznicki, B. J., & Bereznicki, L. (2018) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248418770201 · Cited by 41
Stroke type and severity in patients with subclinical atrial fibrillation: An analysis from the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT)
Perera, K. S., Sharma, M., Connolly, S. J., Wang, J., Gold, M. R., Hohnloser, S. H., Lau, C., Gelder, I. C. V., Morillo, C. A., Capucci, A., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.03.027 · Cited by 40
Resuming anticoagulants after anticoagulation-associated intracranial haemorrhage: systematic review and meta-analysis
Zhou, Z., Yu, J., Carcel, C., Delcourt, C., Shan, J., Lindley, R. I., Neal, B. C., Anderson, C. S., & Hackett, M. L. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-019672 · Cited by 41
Effects of Oral Anticoagulants and Aspirin on Performance of Fecal Immunochemical Tests in Colorectal Cancer Screening
Randel, K. R., Botteri, E., Romstad, K. K., Frigstad, S. O., Bretthauer, M., Hoff, G. S., de Lange, T., & Holme, Ø. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.040 · Cited by 41
Extended Risk Factors for Stroke Prevention
Zhang, S., Zhang, W., & Zhou, G. (2019) · Journal of the National Medical Association · doi:10.1016/j.jnma.2019.02.004 · Cited by 49
Contemporary best practice in the management of pulmonary embolism during pregnancy
Wiegers, H. M. G., & Middeldorp, S. (2020) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466620914222 · Cited by 45
Does One Dose Really Fit All? On the Monitoring of Direct Oral Anticoagulants: A Review of the Literature
Moner-Banet, T., Alberio, L., & Bart, P. (2020) · Hämostaseologie · doi:10.1055/a-1113-0655 · Cited by 41
Non–Vitamin K Antagonist Oral Anticoagulant vs Warfarin for Post Cardiac Surgery Atrial Fibrillation
Nauffal, V., Trinquart, L., Osho, A. A., Sundt, T. M., Lubitz, S. A., & Ellinor, P. T. (2021) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2020.12.031 · Cited by 41
Stroke Prevention in Older Adults
Spence, J. D., Azarpazhooh, M. R., Larsson, S. C., Bogiatzi, C., & Hankey, G. J. (2020) · Stroke · doi:10.1161/strokeaha.120.031707 · Cited by 43
Coagulation Abnormalities in Heart Failure: Pathophysiology and Therapeutic Implications
Kim, J. H., Shah, P. M., Tantry, U. S., & Gurbel, P. A. (2016) · Current Heart Failure Reports · doi:10.1007/s11897-016-0308-6 · Cited by 41
The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society
Jung, B. C., Kim, N. H., Nam, G. B., Park, H. W., On, Y. K., Lee, Y. S., Lim, H. E., Joung, B., Cha, T. J., Hwang, G., et al. (2015) · Korean Circulation Journal · doi:10.4070/kcj.2015.45.1.9 · Cited by 40
Stability of International Normalized Ratios in Patients Taking Long-term Warfarin Therapy
Pokorney, S. D., Simon, D. N., Thomas, L. E., Gersh, B. J., Hylek, E. M., Piccini, J. P., & Peterson, E. D. (2016) · JAMA · doi:10.1001/jama.2016.9356 · Cited by 40
Stroke and Cardiovascular Events After Ablation or Antiarrhythmic Drugs for Treatment of Patients With Atrial Fibrillation
MANSOUR, M. C., Heist, E. K., Agarwal, R., Bunch, T. J., Karst, E., Ruskin, J. N., & Mahapatra, S. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.01.043 · Cited by 39
Efficacy and Safety of Direct Oral Anticoagulants for Stroke Prevention in Older Patients With Atrial Fibrillation: A Network Meta‐Analysis of Randomized Controlled Trials
Lin, D. S., Lo, H., Huang, K., Lin, T., & Lee, J. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030380 · Cited by 39
Twice- or Once-Daily Dosing of Novel Oral Anticoagulants for Stroke Prevention: A Fixed-Effects Meta-Analysis with Predefined Heterogeneity Quality Criteria
Clemens, A., Noack, H., Brueckmann, M., & Lip, G. Y. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099276 · Cited by 41
Underuse of anticoagulation in patients with atrial fibrillation
Vallakati, A., & Lewis, W. R. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2016.1132939 · Cited by 40
Risk–Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies
Raschi, E., Bianchin, M., Ageno, W., Ponti, R. D., & Ponti, F. D. (2016) · Drug Safety · doi:10.1007/s40264-016-0464-3 · Cited by 41
Effect of New Oral Anticoagulants on Prescribing Practices for Atrial Fibrillation in Older Adults
Fohtung, R. B., Novak, E. L., & Rich, M. W. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15058 · Cited by 40
Stroke Prevention for Patients with Atrial Fibrillation: Beyond the Guidelines
McIntyre, W. F., & Healey, J. S. (2017) · Journal of Atrial Fibrillation · doi:10.4022/jafib.1475 · Cited by 40
Non-vitamin K Antagonist Oral Anticoagulants and Cognitive Impairment in Atrial Fibrillation: Insights From the Meta-Analysis of Over 90,000 Patients of Randomized Controlled Trials and Real-World Studies
Zhang, C., Gu, Z., Shen, L., Pan, M.-M., Yan, Y., Pu, J., Liu, X.-Y., & Lin, H. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00258 · Cited by 41
Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation
Coleman, C. I., Brière, J., Fauchier, L., Lévy, P., Bowrin, K., Toumi, M., Millier, A., Taieb, V., & Wu, O. (2019) · Journal of Market Access & Health Policy · doi:10.1080/20016689.2019.1574541 · Cited by 40
Four-year trends in oral anticoagulant use and declining rates of ischemic stroke among 194,030 atrial fibrillation patients drawn from a sample of 12 million people
Maggioni, A. P., Dondi, L., Andreotti, F., Pedrini, A., Calabria, S., Ronconi, G., Piccinni, C. P., & Martini, N. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.10.017 · Cited by 41
Treatment of atrial fibrillation: a comprehensive review and practice guide
Li, J., Gao, M., Zhang, M., Liu, D., Li, Z., Du, J., & Hou, Y. (2020) · Cardiovascular journal of South Africa/Cardiovascular journal of Southern Africa · doi:10.5830/cvja-2019-064 · Cited by 42
Long-Term Risk of Major Adverse Cardiac Events in Atrial Fibrillation Patients on Direct Oral Anticoagulants
Pastori, D., Menichelli, D., Sole, F. D., Pignatelli, P., Violi, F., Casciaro, M., Saliola, M., Carnevale, R., & Russis, M. D. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.06.057 · Cited by 40
Automatic Mobile Health Arrhythmia Monitoring for the Detection of Atrial Fibrillation: Prospective Feasibility, Accuracy, and User Experience Study
Santala, O. E., Halonen, J., Martikainen, S., Jäntti, H., Rissanen, T. T., Tarvainen, M. P., Laitinen, T. P., Laitinen, T. M., Väliaho, E., Hartikainen, J. E. K., et al. (2021) · JMIR mhealth and uhealth · doi:10.2196/29933 · Cited by 40
Guía ESC/EACTS 2021 sobre el diagnóstico y tratamiento de las valvulopatías
Vahanian, A. S., Beyersdorf, F., Praz, F., Milojevic, M., Baldus, S. E., Bauersachs, J. K., Capodanno, D., Conradi, L., Bonis, M. D., Paulis, R. D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.11.023 · Cited by 45
Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions
Monaco, L., Biagi, C., Conti, V., Melis, M., Donati, M., Venegoni, M., Vaccheri, A., & Motola, D. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13234 · Cited by 40
Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios
Chang, T., Liao, J., Chao, T., Vicera, J. J. B., Lin, C., Tuan, T., Lin, Y., Chang, S., Lo, L., Hu, Y., et al. (2018) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2018.08.003 · Cited by 38
Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials
Schnabel, R. B., Benezet‐Mazuecos, J., Becher, N., McIntyre, W. F., Fierenz, A., Lee, S. F., Goette, A., Atar, D., Bertaglia, E., Benz, A. P., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae596 · Cited by 43
Myocardial infarction and atrial fibrillation: Different impact of anti-IIa vs anti-Xa new oral anticoagulants
Loffredo, L., Perri, L., & Violi, F. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.10.124 · Cited by 39
Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials
Renda, G., Nicola, M. D., & Caterina, R. D. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.03.034 · Cited by 40
Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects
Reilly, P. A., van Ryn, J., Grottke, O., Glund, S., & Stangier, J. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.06.007 · Cited by 39
Effect of Activated Charcoal on Rivaroxaban Complex Absorption
Ollier, É., Hodin, S., Lanoiselée, J., Escal, J., Accassat, S., Magalhaes, É. D., Basset, T., Bertoletti, L., Mismetti, P., & Delavenne, X. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0485-1 · Cited by 39
Should We Perform Catheter Ablation for Asymptomatic Atrial Fibrillation?
Kalman, J. M., Sanders, P., Rosso, R., & Calkins, H. G. (2017) · Circulation · doi:10.1161/circulationaha.116.024926 · Cited by 42
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis
Caldeira, D., David, C., Costa, J. N., Ferreira, J. J., & Pinto, F. J. (2017) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvx028 · Cited by 39
Analysis of risk factors for colonic diverticular bleeding and recurrence
Taki, M., Oshima, T., Tozawa, K., Taniguchi, Y., Tomita, T., Ohda, Y., Fukui, H., Watari, J., & Miwa, H. (2017) · Medicine · doi:10.1097/md.0000000000008090 · Cited by 39
Addressing Multimorbidity and Polypharmacy in Individuals With Atrial Fibrillation
Shaikh, F., Pasch, L. B., Newton, P. J., Bajorek, B. V., & Ferguson, C. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-0975-x · Cited by 39
Updates on Prevention of Cardioembolic Strokes
Topçuoğlu, M. A., Liu, L., Kim, D., & Gurol, M. E. (2018) · Journal of Stroke · doi:10.5853/jos.2018.00780 · Cited by 40
Effectiveness and safety of non-vitamin-K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with thrombocytopenia
Wang, C., Wu, V. C., Lee, C., Kuo, C., Chen, Y., Chu, P., Chen, S., Wen, M., See, L., & Chang, S. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1792-1 · Cited by 40
Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice
Corsini, A., Ferri, N., Proietti, M., & Boriani, G. (2020) · Drugs · doi:10.1007/s40265-020-01328-6 · Cited by 39
Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants—a Swedish, register-based cohort study in atrial fibrillation outpatients
Holm, J., Mannheimer, B., Malmström, R. E., Eliasson, E., & Lindh, J. D. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-03015-7 · Cited by 39
Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries
Komen, J. J., Pottegård, A., Mantel-Teeuwisse, A. K., Forslund, T., Hjemdahl, P., Wettermark, B., Hellfritzsch, M., Hallas, J., Olesen, M. S., Bennie, M., et al. (2021) · EP Europace · doi:10.1093/europace/euab091 · Cited by 39
Trends in Incidence of Intracerebral Hemorrhage and Association With Antithrombotic Drug Use in Denmark, 2005-2018
Hald, S. M., Möller, S., Rodríguez, L. A. G., Salman, R. A., Sharma, M., Christensen, H., Hellfritzsch, M., Pottegård, A., Hallas, J., & Gaist, D. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.8380 · Cited by 41
Anticoagulant prescribing for atrial fibrillation and risk of incident dementia
Cadogan, S. L., Powell, E. M., Wing, K., Wong, A. Y. S., Smeeth, L. L., & Warren‐Gash, C. (2021) · Heart · doi:10.1136/heartjnl-2021-319672 · Cited by 39
Early versus late start of direct oral anticoagulants after acute ischaemic stroke linked to atrial fibrillation: an observational study and individual patient data pooled analysis
Marchis, G. M. D., Seiffge, D. J., Schaedelin, S. A., Wilson, D., Caso, V., Acciarresi, M., Tsivgoulis, G. K., Koga, M., Yoshimura, S., Toyoda, Ḱ., et al. (2021) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-327236 · Cited by 40
Thirty‐day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life‐threatening direct oral anticoagulant‐related bleeding
Cohen, A. T., Lewis, M., Connor, A., Connolly, S. J., Yue, P., Curnutte, J. T., Alikhan, R., MacCallum, P., Tan, J., & Green, L. (2022) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.12655 · Cited by 38
Efficacy and Safety of Oral Anticoagulants for Atrial Fibrillation Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis
Rhee, T., Lee, S., Choi, E., Oh, S., & Lip, G. Y. H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.885548 · Cited by 41
Vitamin K Antagonists and Risk of Subdural Hematoma
Connolly, B. J., Pearce, L. A., & Hart, R. G. (2014) · Stroke · doi:10.1161/strokeaha.114.005430 · Cited by 39
Thrombin, a Key Driver of Pathological Inflammation in the Brain
Iannucci, J., & Grammas, P. (2023) · Cells · doi:10.3390/cells12091222 · Cited by 40
Management of Gastrointestinal Bleeding and Resumption of Oral Anticoagulant Therapy in Patients with Atrial Fibrillation: A Multidisciplinary Discussion
Martin, A., Benamouzig, R., Gouin‐Thibault, I., & Schmidt, J. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00582-9 · Cited by 38
Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures
Deutsch, D., Boustière, C., Ferrari, É., Albaladejo, P., Morange, P., & Benamouzig, R. (2017) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x17702092 · Cited by 40
ANMCO/AIAC/SICI-GISE/SIC/SICCH Consensus Document: percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation patients: indications, patient selection, staff skills, organisation, and training
Casu, G., Gulizia, M. M., Molon, G., Mazzone, P., Audo, A., Casolo, G., Lorenzo, E. D., Portoghese, M., Pristipino, C., Ricci, R. P., et al. (2017) · European Heart Journal Supplements · doi:10.1093/eurheartj/sux008 · Cited by 40
Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study
Okumura, K., Lip, G. Y. H., Akao, M., Tanizawa, K., Fukuzawa, M., Abe, K., Akishita, M., & Yamashita, T. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.08.017 · Cited by 38
Prevalence of Non-valvular Atrial Fibrillation Based on Geographical Distribution and Socioeconomic Status in the Entire Korean Population
Lee, S., Choi, E., Han, K., Cha, M., & Oh, S. (2018) · Korean Circulation Journal · doi:10.4070/kcj.2017.0362 · Cited by 38

Authors: Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., Yamashita, T., & Antman, E. M.
Affiliations: Brigham and Women's Hospital (US)
Thomas Jefferson University (US)
St George's, University of London (GB)
Thrombosis and Atherosclerosis Research Institute (CA)
Carmel Medical Center (IL)
Cardiovascular Institute Hospital (JP)
Corresponding author: Ruff, Christian T
ORCID: Ruff, Christian T
Giugliano, Robert P
Ezekowitz, Michael D
Camm, A John
Weitz, Jeffrey I
Lewis, Basil S
Parkhomenko, Alexander
Yamashita, Takeshi
Antman, Elliott M
Venue: The Lancet
Publisher: Elsevier BV
Published: 2014-03
Volume: 383
Issue: 9921
Pages: 955-962
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(13)62343-0
OpenAlex: W2152623033
Cited by: 5,051
References: 45
Citations by year: 2026: 249 · 2025: 310 · 2024: 399 · 2023: 426 · 2022: 410 · 2021: 490 · 2020: 521 · 2019: 462 · 2018: 456 · 2017: 447 · 2016: 406 · 2015: 318 · 2014: 139
FWCI: 49.57
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
Keywords: direct oral anticoagulants, warfarin, atrial fibrillation, stroke prevention, systemic embolism, hemorrhagic stroke, intracranial hemorrhage, gastrointestinal bleeding, major bleeding, all-cause mortality, subgroup analysis, factor Xa inhibitors, dabigatran, rivaroxaban, apixaban
MeSH terms: Administration, Oral, Anticoagulants, Atrial Fibrillation, Embolism, Humans, Warfarin, Randomized Controlled Trials as Topic, Treatment Outcome, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks